Panel: Examining Challenges in DDR Target Development to Overcome Translational Barriers & Strengthen Future Development Strategies

• Highlighting the key reasons DDR programs stall, including weak mechanistic rationale, limited biomarker support, and poor patient stratification

• Presenting real-world case studies from biotech and academia on programs that failed to translate, and the lessons learned

• Exploring how early decisions around target selection, dosing, and trial design impact clinical success

• Identifying practical strategies to improve target validation, including functional assays, predictive biomarkers, and more robust preclinical models

Speakers:

Ioannis Gounaris

Vice President - Clinical Development

EMD Serono, an affiliate of Merck KGaA

Jann Sarkaria

consultant

Mayo Clinic

Sotirios Sotiriou

Principal Scientist

Roche

Alan D’Andrea

Director of the Center for DNA Damage and Repair

Dana-Farber Cancer Institute

Jatinder Mukker

Head Senior Director, Quantitative Pharmacology Portfolio Section

EMD Serono, an affiliate of Merck KGaA